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Abstract
Background
A major unmet need for Systemic Sclerosis (SSc) clinical management is the lack of biomarkers for the early diagnosis of patients with Raynaud’s Phenomenon at high risk of
evolving into SSc.

Objective
To identify proteins contained within serum exosomes employing an aptamer proteomic
analysis that may serve to reveal patients with Raynaud’s Phenomenon at risk of developing
SSc.

Methods
Exosomes were isolated from serum samples from patients with Primary Raynaud’s Phenomenon and from patients with Raynaud’s Phenomenon harbouring serum antinuclear
antibodies (ANA) who may be at high risk of evolving into SSc. The expression of 1,305 proteins was quantified using SOMAscan aptamer proteomics, and associations of the differentially elevated or reduced proteins with the clinical subsets of Raynaud’s Phenomenon were
assessed.

Results
Twenty one differentially elevated and one differentially reduced (absolute fold change >|
1.3|) proteins were identified. Principal component analysis using these 22 most differentially expressed proteins resulted in excellent separation of the two Raynaud’s Phenomenon
clinical subsets. Remarkably, the most differentially elevated proteins are involved in
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enhanced inflammatory responses, immune cell activation and cell migration, and abnormal
vascular functions.

Conclusion
Aptamer proteomic analysis of circulating exosomes identified differentially elevated or
reduced proteins between Raynaud’s Phenomenon at high risk of evolving into SSc and Primary Raynaud’s Phenomenon patients. Some of these proteins are involved in relevant biological pathways that may play a role in SSc pathogenesis including enhanced inflammatory
responses, immune cell activation, and endothelial cell and vascular abnormalities.

Introduction
Systemic Sclerosis (SSc) is a serious, disabling, and often fatal systemic autoimmune disease of
unknown cause characterized by a severe and usually progressive cutaneous and visceral
fibrotic process accompanied by extensive fibroproliferative vasculopathy and by humoral,
and cellular immunity alterations [1–4]. One of the most common and earliest clinical manifestations of SSc is Raynaud’s Phenomenon [5–8]. However, Raynaud’s Phenomenon is also
relatively common in the general population. Whereas Primary Raynaud’s Phenomenon is a
benign condition usually evolving without any internal organ damage or increased mortality
risk, Raynaud’s Phenomenon that may evolve into SSc clearly displays a more serious prognosis [5–8]. Therefore, there is a very important need to accurately establish which patients
affected by Raynaud’s Phenomenon will remain as Primary Raynaud’s Phenomenon and
which patients may be at risk of developing SSc before more serious clinical manifestations or
internal organ involvement become apparent.
Although, there has been remarkable recent progress in the application of proteomic analysis of serum and other biological fluids for the identification of SSc biomarkers, most of these
studies have employed mass spectrometry [9–11]. However, mass spectrometry involves complex and time consuming procedures and the overshadowing of proteins present at low concentrations by high abundance proteins represent strong limitations to its widespread
application. The introduction of novel aptamer technologies that allow identification and
simultaneous quantification of a large number of proteins with extremely high sensitivity and
specificity across the entire dynamic range of protein concentrations may overcome these limitations. The remarkable increase in the sensitivity of aptamer proteomics and its high reproducibility in comparison to other more established and generally accepted proteomic
platforms has been extensively demonstrated [12–15].
There has been recent interest in the characterization of proteins contained within secreted
microvesicles for their potential as possible biomarkers for various diseases. Exosomes comprise a well-defined subtype of microvesicles released from all human cells into their surrounding intercellular space and into the circulation [16–20]. Exosomes are identified based on their
size (30–150 nm or 30–200 nm), the mechanisms of their biogenesis and secretion from cells,
and their unique macromolecule content that includes nucleic acids (DNA fragments,
mRNAs, non-coding RNAs and miRNAs), proteins, and lipids [19–22]. It has been shown that
the macromolecular content of exosomes depends on their cell of origin and, more importantly, reflects the functional or pathologic status of the cells [23]. Therefore, there has been
great interest in the study of exosomal content as a source of potential diagnostic biomarkers
for a variety of diseases, for the assessment of disease extent and severity, and to evaluate and
monitor response to therapeutic interventions [21,22].
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Owing to the extremely high sensitivity and specificity inherent in the developing field of
aptamer proteomics, their application for the characterization and quantitative analysis of the
protein content of serum and other biological fluids should be expected to yield highly valuable
and novel disease biomarkers [24–27]. Indeed, some recent studies employed aptamer proteomics to analyze the proteomic content of serum from patients with various disorders including
SSc [28,29]. These studies demonstrated a tremendous potential of aptamers for the discovery
and identification of non-invasive biomarkers for numerous human disorders, and it is likely
that aptamer proteomic analysis should continue to expand enhancing their value as diagnostic tools in the rapidly developing field of individualized medicine.
In the present study, we applied aptamer proteomic analyses of exosomes isolated from
serum from patients with Raynaud’s Phenomenon who harbored in their serum a positive
ANA test in comparison with patients with Primary Raynaud’s Phenomenon who had a negative ANA test. Our main objective was to identify differentially elevated or decreased proteins
that may allow to separate patients who may be at high risk of developing SSc or who may be
at the very early stages of SSc development [30].

Materials and methods
Population cohorts
The patients included in the study were enrolled and followed at the Scleroderma Center of
Thomas Jefferson University (Philadelphia, PA, USA). There were 4 subjects with Raynaud’s
Phenomenon with negative ANA and 3 subjects with Raynaud’s Phenomenon with positive
ANA. All subjects were white females, their ages ranged from 21 to 53 years, and the duration
of the Raynaud’s Phenomenon symptoms was from 1 to 11 years. The diagnosis of Raynaud’s
Phenomenon was made based on the clinical manifestations presented by the subjects and on
detailed physical examination. The diagnosis was in agreement with the criteria described in
previous publications on Raynaud’s Phenomenon [5–7] and the International Consensus Criteria for the diagnosis of Raynaud’s Phenomenon [8]. At the time the samples were obtained
for this study, none of the subjects had Sclerodactily, skin induration or other clinical manifestations of SSc. All patients also had serologic tests for a broad spectrum of autoantibodies. The
serum ANA titers were 1:160 or greater in the cohort with positive ANA, and the patterns at
the initial evaluation were anticentromere in one, speckled in another one, and homogeneous
in the third subject. Of the relevance to the diagnosis of SSc was the fact that each of these
patients developed Scl-70 antibodies at subsequent evaluations, thus providing strong support
to the diagnosis of SSc in this cohort.

Exosome isolation
Blood samples were obtained following approval of the Institutional Review Board (IRB). The
IRB also approved the establishment of a serum biorepository at the Scleroderma Center (Protocol Title: “Biochemical and Vascular Alterations in Scleroderma”; IRB Protocol #06F.186).
Serum samples were aliquoted and stored at -80˚C until assayed. Exosomes were isolated from
0.5 ml of serum by size exclusion chromatography using the SBI (Scientific Bioscience, Palo
Alto, CA.) SmartSEC HT EV Isolation System according to the manufacturer’s instructions.
Essentially all of the microvesicles isolated employing this procedure are less than 200 nm
according to the manufacturer’s brochure. For exosome protein extraction, the isolated exosomes were suspended in 1.0 ml of exosome buffer and proteins were extracted from 0.5 ml of
each exosome sample using the M-PER extraction buffer (ThermoFisher Scientific, Watham,
MA.) which yielded enough protein to proceed with SOMAscan analysis.
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SOMAscan assay
SOMAscan1 analysis (SomaLogic, Inc., Boulder, CO) was performed in duplicate from samples of each patient included in the study. The analysis was performed at the BIDMC Genomics, Proteomics, Bioinformatics, and Systems Biology Center of Beth Israel Deaconess
Medical Center (Boston, MA), an experienced SomaLogic certified service provider, according
to standard protocols from SomaLogic that have been described elsewhere [31,32] using exosomes isolated at the Scleroderma Center of Thomas Jefferson University from the serum of
the two Raynaud’s Phenomenon patient cohorts listed above. Briefly, using the recommended
protocol from the manufacturer, 7.2 μg of sample of exosome protein lysate from each patient
included in the study was run on the SOMAscan1 Assay Kit for cell/tissue lysates 1.3k. This
assay measures the concentration levels of 1,305 human proteins using highly selective singlestranded modified Slow Off-rate Modified DNA Aptamers (SOMAmer). Each individual protein concentration was transformed into a corresponding SOMAmer concentration, then
quantified using a custom DNA microarray (Agilent) read-out which reports the data as relative fluorescence units (RFU), as described previously [31,32]. Three pooled normal serum
exosome controls and one no-protein buffer control were run in parallel with the exosome test
samples. Sample to sample variability was further controlled by several hybridization spike-in
controls. Data quality control, calibration, and normalization were performed by SomaLogic
according to the manufacturer’s protocol, as previously described [31,32]. All samples passed
the SomaLogic standard quality control and normalization criteria for the manual 1.3k assay.
Alterations in the expression of the identified proteins were analysed using the Student t test as
described previously [31,32].

Statistical analysis
Mean- and median fold-changes (FC) were calculated for proteins with statistically significant
different concentration levels between the two Raynaud’s Phenomenon groups. Statistical significance was determined by using a t-test to compare SOMAscan1 relative fluorescence
units. Owing to the relatively small number of samples included in this study a protein was
considered to be significantly elevated or decreased if the median absolute fold change was >|
1.3| and the p-value was <0.1 as described previously [31,32]. Principal component analysis
(PCA) was performed using XLSTAT (Addinsoft, Long Island City, NY) for the proteins with
the largest increase or decrease in concentration to evaluate their ability to discriminate the
two Raynaud’s Phenomenon clinical subsets.

Systems Biology Analysis
To acquire new insights into potential pathophysiological pathways and biological functions
underlying the exosomal protein signatures associated with the pathogenetic-difference or
with the progression of patients with Raynaud’s Phenomenon and negative ANA to patients
with Raynaud’s Phenomenon with positive ANA and to more precisely understand the complex interactions between the differentially increased or decreased proteins and potential candidate upstream regulators that may be involved in the progression or development of very
early SSc, extensive Systems Biology Analysis was performed. These studies included assessment of functional category, upstream regulator, and regulator effect analyses of all dysregulated proteins with a p-value <0.1 and FC>|1.3| using the Ingenuity Pathway Analysis (IPA)
software tool (QIAGEN, Redwood City, CA) as described previously [31,32]. The IPA software
tool allows access to a repository of biological interactions and functions created from millions
of individually modelled relationships ranging from the molecular (proteins, genes) to the
organism (diseases) levels. The same top dysregulated proteins with a p-value <0.1 and FC>|
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1.3| were included in further network analysis using the STRING database version 11.0 for
protein-protein functional and physical interactions, the results of which were displayed as a
functional network. Interactions were considered with a medium confidence score of 0.4 or
higher. Proteins without associations to other proteins in the network were removed. A kmeans clustering algorithm was performed to select connected proteins (k-means = 3). Functional description of clusters was assigned based on a manually curated evaluation of enriched
KEGG pathway, Gene Ontology (GO), Reactome, and STRING local network clusters terms.

Results
SOMAscan proteomics analysis
SOMAscan analysis comparing Raynaud’s Phenomenon with positive ANA to Primary Raynaud’s Phenomenon (with negative ANA) identified 22 dysregulated proteins with an absolute
fold change of >|1.3| and a p value of <0.1 (21 increased, 1 decreased) as listed in Table 1.
Principal component analysis (PCA) using as input the top 22 differentially elevated or
reduced proteins resulted in excellent separation of the two Raynaud’s Phenomenon cohorts,
demonstrating that SOMAscan aptamer proteomics, indeed, identifies exosome proteins that
clearly discriminate between the two clinical phenotypes as shown in Fig 1.
Table 1. Top elevated (>1.30-fold and p value <0.1) and decreased (<1.30-fold and p value <0.1) proteins from serum exosomes of patients with Raynaud’s Phenomenon with positive ANA compared with serum exosomes from patients with Raynaud’s Phenomenon with negative ANA identified by aptamer proteomics.
Increased in Raynaud’s Phenomenon with Positive ANA
SomaId

TargetFullName

Entrez Gene Symbol

p-val

Mean FC

Median Fc

SL000019

Apolipoprotein A-I (Apo A-1)

APOA1

0.045

5.66

7.18

SL004511

Bactericidal permeability-increasing protein (BPI)

BPI

0.065

2.76

2.89

SL000466

Insulin-like growth factor-binding protein 2 (IGFBP2)

IGFBP2

0.022

2.17

2.49

SL004009

Ras-related C3 botulinum toxin substrate 1 (RAC1)

RAC1

0.076

2.43

2.14

SL004516

Mannose-binding protein C (MBL)

MBL2

0.081

1.83

2.02

SL004765

MAP kinase-activated protein kinase 3 (MAPKAPK3)

MAPKAPK3

0.047

1.83

1.95

SL008039

Alcohol dehydrogenase [NADP(+)] (AK1A1)

AKR1A1

0.075

1.99

1.83

SL002782

Adrenomedullin

ADM

0.089

1.60

1.79

SL006542

Ficolin-2 (FCN2)

FCN2

0.053

1.60

1.72

SL003744

Galectin-3

LGALS3

0.035

2.03

1.71

SL000247

6-phosphogluconate dehydrogenase

PGD

0.077

1.53

1.60

SL000406

Eotaxin

CCL11

0.094

1.44

1.60

SL003522

Endoplasmic reticulum resident protein 29 (ERP29)

ERP29

0.094

1.39

1.57

SL018548

Alpha-1-antichymotrypsin complex

SERPINA3

0.050

1.42

1.49

SL004438

Cystatin-M

CST6

0.054

1.63

1.49

SL010384

Testican-1

SPOCK1

0.089

1.61

1.44

SL000617

Alanine aminotransferase 1 (ALT)

GPT

0.028

1.53

1.42

SL007173

Granulins (GRN)

GRN

0.023

1.35

1.35

SL003722

RAC-beta serine/threonine-protein Kinase (PKB beta)

AKT2

0.060

1.34

1.32

SL004556

Complement decay- accelerating factor (DAF)

CD55

0.086

1.29

1.31

SL005214

Semaphorin- 6A

SEMA6A

0.002

1.29

1.31

Decreased in Raynaud’s Phenomenon with Positive ANA
SomaId

TargetFullName

EntrezGeneSymbol

p-val

mean FC

Median Fc

SL000310

Complement C1r subcomponent (C1r)

C1R

0.035

-2.14

-1.93

ANA: Serum antinuclear autoantibodies.
SomaId: SomaLogic identification number.
https://doi.org/10.1371/journal.pone.0279461.t001
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Fig 1. Principal component analysis of exosome proteins from patients with Raynaud’s Phenomenon with positive ANA compared to
patients with Raynaud’s Phenomenon with negative ANA. Principal Component analysis of 22 differentially expressed proteins between
samples of patients with Raynaud’s Phenomenon with negative ANA (green) and patients with Raynaud’s Phenomenon with a positive
ANA (red).
https://doi.org/10.1371/journal.pone.0279461.g001

Systems Biology Analysis of dysregulated pathways
To acquire new insights into potential pathophysiological pathways underlying the serumderived exosome protein signature associated with ANA positive Raynaud’s Phenomenon, we
performed functional category and upstream regulator analysis of the 22 dysregulated proteins
with a p<0.1 and a fold difference >|1.3| using the Ingenuity Pathway Analysis (IPA) software
tool (QIAGEN, Redwood City, CA). The Biofunction Analysis shown in Fig 2 demonstrated
that even among the relatively small number of samples used for analysis, the majority of the
differentially expressed proteins were not a random set of proteins but were enriched for specific pathways (Fig 2A) and networks (Fig 2B–2D), showing clear biological relationships.
Most prominent and with highest statistical significance of enrichment were pathways linked
to vascular functions (Endothelial cell development; Proliferation of endothelial cells; Vasculogenesis), inflammation (Inflammation of body cavity; Inflammation of absolute anatomical
region; Inflammation of organ), and myeloid cell movement and binding (Binding of professional phagocytic cells; Binding of myeloid cells; Cell movement of granulocytes; Cell movement of myeloid cells; Cell movement of phagocytes; Cell movement of neutrophils; Binding
of monocytes).
Especially informative was modelling the links between differentially expressed proteins
based on their established connections with predicted upstream regulatory proteins. Upstream
Regulator analysis predicted multiple proteins as potential regulators of these differentially elevated or reduced exosome proteins (Fig 3A). Most of the predicted upstream regulators with
highest statistical significance for dysregulated proteins discriminating between Raynaud’s
Phenomenon with positive ANA vs Primary Raynaud’s Phenomenon converged on activation
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Fig 2. Biofunction analysis of exosome proteins from serum samples from patients with Raynaud’s Phenomenon with positive ANA compared to
patients with Raynaud’s Phenomenon with negative ANA. A: Functional category. B-D: Biological Interactions: Inflammatory process (B); Immune response
(C); and Endothelial cell and vascular involvement (D). IPA color and symbol guide: Blue = inhibition; orange = activation; red = increased; green = decreased;
yellow = contrary to published evidence; grey = unknown; dashed line = indirect; arrowhead (pointed) = activating; arrowhead (blunt) = inhibitory. Proteins
are coded by shape; square: Cytokine, vertical rhombus: Enzyme, horizontal rhombus: Peptidase, trapezoid: Transporter, ellipse: Transmembrane receptor,
circle: Other.
https://doi.org/10.1371/journal.pone.0279461.g002

of pro-inflammatory and immunoregulatory proteins (TNF0α, NFKβ, NFKBIA, IL15) and
extracellular matrix (TGFβ1) and vascular function regulators (AGT) (Fig 3A). These results
indicated that these signalling nodes may be involved in the dysregulation of a sizeable portion
of the top 22 proteins in the exosome proteomic signature for Raynaud’s Phenomenon with
positive ANA compared with Primary Raynaud’s Phenomenon. Of substantial relevance in
this regard were the observations that TGFβ1 regulated 9 out of the top 22 dysregulated proteins (Fig 3B), but remarkably, none of these were the typical profibrotic proteins associated
with TGFβ. The results also showed that a key positive regulator of protein expression was the
pro-inflammatory cytokine TNFα that was predicted to regulate 11 out of the top 22 dysregulated proteins (Fig 3C). These results strongly indicated that a potential increase in inflammatory processes may represent a crucial event that differentiates patients with Primary
Raynaud’s Phenomenon from patients with the phenotype of Raynaud’s Phenomenon with
positive ANA. This notion is further enhanced by the prediction of the pro-inflammatory transcription factor NFKβ as a positive regulator of 6 of these proteins (Fig 3D) and was also
reflected in the biological functions significantly enriched in Raynaud’s Phenomenon with
positive ANA compared with Primary Raynaud’s Phenomenon. These biological function
included predicted enhanced migration, movement, binding, and immune response of myeloid cells, granulocytes, and phagocytes linked to 11 proteins (Fig 2). Ten proteins were also
predicted to enhance vasculogenesis and endothelial cell proliferation (Fig 2A and 2D) and a
regulator model predicted by IPA highlighted TGFβ and TNFα as positive upstream regulators
of numerous proteins that are anticipated to modulate vasculogenesis (Fig 3B and 3C).
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Fig 3. Upstream regulator analysis (A), downstream targets for TGFβ (B), for TNFα (C), and for NFKβ (D) of exosome proteins from patients
with Raynaud’s Phenomenon with positive ANA compared to patients with Raynaud’s Phenomenon with negative ANA. IPA color and symbol
guide: Blue = inhibition; orange = activation; red = increased; green = decreased; yellow = contrary to published evidence; grey = unknown;
dashed line = indirect; arrowhead (pointed) = activating; arrowhead (blunt) = inhibitory. Proteins are coded by shape; square: Cytokine, vertical
rhombus: Enzyme, horizontal rhombus: Peptidase, trapezoid: Transporter, ellipse: Transmembrane receptor, circle: Other.
https://doi.org/10.1371/journal.pone.0279461.g003

Next, we performed network and cluster analysis using the STRING database of functional
and physical protein associations curated across major data repositories (Fig 4). Twelve of the
22 proteins discriminating between Raynaud’s Phenomenon with positive ANA and Primary
Raynaud’s Phenomenon formed distinct interacting protein clusters with links to immune
response and the complement system (Fig 4). An alternative interactive network analysis was
performed using as input the most differentially expressed proteins from the comparison
between the two Raynaud’s Phenomenon subsets using IPA that also incorporates genes/proteins that are not differentially expressed but directly connected. The results showed that the
largest number of the differentially elevated proteins from the samples of patients with Raynaud’s positive ANA are predicted to participate in JNK/ERK and AKT/RAC1 networks as
shown by these proteins as focus hubs. These focus hubs contain proteins with the most connections, that are thought to be functionally critical for the network and whose interruption
would be expected to have a substantial/profound biological impact as shown in Fig 5.

Discussion
One of the most common and earliest clinical manifestations of SSc is Raynaud’s Phenomenon
[5–7]. A large study by Koenig et al. indicated that Raynaud’s Phenomenon associated with
the presence of swollen or puffy fingers and a positive serum ANA was predictive of the progression to SSc [30]. Since the appearance of a positive ANA test in the serum may be slow to
develop, it is crucially important to identify earlier biomarkers that may help to accurately

PLOS ONE | https://doi.org/10.1371/journal.pone.0279461 December 22, 2022

8 / 15

PLOS ONE

Aptamer proteomics of Raynaud’s phenomenon serum exosomes

Fig 4. STRING analysis of exosome proteins from patients with Raynaud’s Phenomenon with positive ANA
compared to patients with Raynaud’s Phenomenon with negative ANA. Protein–protein interaction network was
created based on analysis of 12 proteins out of 22 proteins from the comparison of samples with Raynaud with positive
ANA vs Raynaud with negative ANA. k-means = 3 clusters indicated by node color. Solid line represents withincluster, dashed lines represent between-cluster interactions.
https://doi.org/10.1371/journal.pone.0279461.g004

establish which patients affected by Raynaud’s Phenomenon may be at risk of developing SSc
before more serious clinical manifestations or internal organ involvement become apparent or
before they develop clinical and pathologic SSc alterations. At the same time, identification of
early disease biomarkers is critical to better understand the pathophysiological processes
involved in the development of SSc clinical manifestations and to provide new insights into
therapeutic strategies for prevention or delay of SSc development.
A highly promising new proteomics technology, SOMAscan, for the analysis and quantification of protein biomarkers employs chemically modified aptamers. Aptamers are RNA molecules that exhibit highly complex molecular recognition properties and are capable of binding
specifically and with high affinity to targets ranging from small molecules to complex multimeric structures [12–15]. Aptamers have a remarkable dynamic detection range encompassing
femtomolar to micromolar concentrations. Owing to its very high sensitivity it is generally
expected that aptamer proteomic technology should enable the quantitative assessment of proteins present at very low concentrations in samples from various biological fluids as well as to
assay for a large number of proteins simultaneously. The aptamer-based proteomic analysis
utilizing the SOMAscan assay is a highly multiplexed, sensitive, quantitative and reproducible
proteomic platform that offers excellent reproducibility and a low coefficient of variability
[12–15]. The SOMAscan assay employed in the current study measures the levels of 1,305 analytes over a wide dynamic range (>10 logs of concentration) with minimal amounts of protein
needed (7.2 μg of exosomal proteins).
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Fig 5. Networks of interacting proteins from exosomes isolated from patients with Raynaud’s Phenomenon and
positive ANA compared with exosomes from patients with Raynaud’s Phenomenon and negative ANA. A:
Network of JNK and ERK interactions; B: Network of AKT and RAC1 interactions. IPA color and symbol guide:
Blue = inhibition; orange = activation; red = increased; green = decreased; yellow = contrary to published evidence;
grey = unknown; dashed line = indirect; arrowhead (pointed) = activating; arrowhead (blunt) = inhibitory. Proteins
are coded by shape; square: Cytokine, vertical rhombus: Enzyme, horizontal rhombus: Peptidase, trapezoid:
Transporter, ellipse: Transmembrane receptor, circle: Other.
https://doi.org/10.1371/journal.pone.0279461.g005

One of the most promising and novel approaches for the discovery of disease biomarkers is
the analysis of exosomes that are isolated and purified from serum, plasma, and other biological fluids. Exosomes are a subtype of extracellular vesicles (EV) that contain a diverse array of
macromolecular species, including multiple forms of nucleic acids (mRNAs, miRNAs and various other non-coding RNAs), proteins (cytokines, chemokines, growth factors and transcription factors), lipids, and other metabolites [16–22]. Since the macromolecular content of
exosomes reflects the cells from which they were released, as well as any functional, pathological or phenotypic changes occurring in these cells [23], the analysis of their macromolecular
content would be expected to yield biomarkers that serve not only as valuable diagnostic tools
for various diseases but also as indicators of disease improvement or progression. Indeed, several studies have described the application of exosome proteomics to identify potential biomarkers for numerous diseases [Reviewed in 19–22]. Moreover, two studies showed that
exosomes were carriers of pro-fibrotic signals [33,34], or that they may function as messengers
between the immune, vascular and fibrotic components in SSc [35]. Despite this promising
potential approach, few aptamer proteomic studies applied to SSc have been described [28,29].
However, these published studies [28,29], did not examine the proteomic content of isolated
SSc serum exosomes.
The results obtained in the current exploratory study identified 22 proteins that were differentially elevated or decreased in the comparative analysis of the two sets of Raynaud’s
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Phenomenon patients that had not been previously considered to be associated with SSc development or pathogenesis. Remarkably, some of these proteins display inflammatory, immunologic and vascular effects. Among these proteins, Apolipoprotein A-1 (Apo A-1) was the
highest differentially elevated protein in the exosomes from patients with Raynaud’s Phenomenon with positive ANA (7.18-fold). Although Apo A-1 is well known to play a crucial role in
maintenance of high density lipoproteins and is recognized as playing a protective role in various cardiovascular events including myocardial infarction, several recent studies have pointed
out that Apo A-1 may also participate in the regulation and development of inflammatory
events [36]. Another protein that was differentially elevated was the mannose binding protein
(MBL2), a liver-based mannose-binding lectin that is a significant constituent of the human
innate immunity and appears to be a major regulator of inflammation [37]. There was also a
nearly three-fold elevation of the bactericidal/permeability-increasing protein (BPI). BPI is a
lipid-transfer protein mainly present in neutrophils, and to a lesser extent in eosinophils that is
endowed with potent and selective antimicrobial and endotoxin-neutralizing properties.
Although, a potential role for BPI in the pathogenesis of autoimmune disorders has not been
described, it has been shown that there is a high prevalence of autoantibodies against BPI
(BPI-ANCA) in serum from patients with various infectious, inflammatory, and rheumatic
diseases [38], and that its overexpression may induce inflammatory events in patients with
SLE [39]. Furthermore, BPI has been shown to inhibit angiogenesis and cause endothelial cell
apoptosis [40].
Several other proteins of interest will be briefly discussed in the following paragraphs. One
of these is IGFBP-2. It has recently been demonstrated that IGFBP-2 may display numerous
activities not related to insulin binding, including some effects on profibrotic and proinflammatory pathways. Indeed, the serum levels of IGFBP-2 were shown to be elevated in SSc patients
with lung vascular involvement compared to healthy donors, and of remarkable importance
were observations that IGFBP-2 levels displayed a negative correlation with pulmonary function
in these patients [41]. Another protein is RAC1, the small GTPase Ras-related C3 botulinum
toxin substrate 1. RAC1 plays a central role in skin homeostasis, including barrier function,
wound healing and inflammatory responses [42]. RAC1 is also involved in the maintenance
and stabilization of microvascular endothelial barrier functions and is essential for wound reepithelialization, therefore, its activity is increased during wound healing [42]. It has also been
shown that RAC1 Inhibition reduces the fibrotic phenotype of activated fibroblasts [43].
Mitogen-activated protein kinases (MAPKs) family of enzymes regulates a diverse array of
physiological processes including cell proliferation and differentiation, development, immune
function, stress responses, and cell death. The MAPK-activated kinase 3 (MAPKAPK3) also
has been implicated in the inflammatory response [44]. Of substantial interest were the results
with Galectin-3 (Gal3) which is a member of the β-galactoside-binding lectin family mainly
found in epithelial and myeloid cells but also found in other cell types including a variety of
immune cells. Gal3 binds various cell receptors and extracellular matrix proteins and selectively mediates key intracellular signaling pathways leading to the release of several cytokines.
Numerous biological functions where Gal3 plays a mediator role have been recognized,
including regulation of extracellular matrix and epithelial cell interactions, cell growth and differentiation, regulation of immune surveillance, angiogenesis and proinflammatory activities.
Recent evidence indicates that Gal3 plays an important role in the pathogenic mechanisms of
tissue fibrosis by increasing fibroblast proliferation and collagen production [45]. Also, some
studies showed higher serum levels of Gal3 in SSc patients compared with normal donors and
described Gal1 and Gal3 associations with SSc clinical features [46,47]. However, in another
study Gal1 and Gal3 expression levels were found to be lower in SSc lesional skin compared
with normal donor skin [48].
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Finally, some studies have examined the levels of α1-antichymotrypsin, also known as SERPIN3A. SERPIN3A protein is an acute-phase reactant produced by the liver. Its biologic function is to inhibit several serine proteases, mainly cathepsin G, which is contained in the
neutrophil granules and released at sites of inflammation. Notably, an excess of cathepsin G
function is linked to tissue damage. Other interesting proteins included among the SERPIN3A
and Lectin pathway proteins have been implicated in SSc and elevated serum levels are associated with renal crisis [49,50].
The novelty of the studies reported here lies in the application of aptamer proteomics for
identification of differentially increased or decreased proteins in extracts from exosomes isolated from the serum of patients with Primary Raynaud’s Phenomenon with negative ANA
compared with patients with Raynaud’s Phenomenon with positive ANA. This later population is considered to be at high risk of evolving into a systemic autoimmune disease, most
likely SSc. Although we acknowledge and are very aware that the number of patients included
in the Raynaud’s Phenomenon cohorts studied here is quite small representing a serious weakness to this study, we believe that the description of the results obtained with samples from
these patients may provide a strong stimulus to perform subsequent studies that may pursue
the study of the novel proteins in SSc pathogenesis and also to identify useful and valuable biomarkers for the diagnosis of patients with Raynaud’s Phenomenon at high risk of evolving into
SSc.
We further recognize that the results described here will require validation in larger populations of patients with Raynaud’s Phenomenon to confirm and demonstrate their clinical utility. However, it is important to emphasize that, currently, there is a serious lack of validated
biomarkers that may allow to identify SSc patients at the earliest stages of SSc development.
This represents an important unmet need since given the serious clinical implications of SSc it
is of crucial importance to establish an early diagnosis that may allow the institution of appropriate therapeutic measures that may be effective to prevent further progression to the development of the full SSc clinical manifestations and high mortality rate. Furthermore, the results
we obtained identified numerous proteins that were differentially elevated in the samples from
ANA + Raynaud’s Phenomenon patients that had not been previously associated with SSc
pathogenesis but that as discussed above participate in important cellular functions that may
be of great relevance to the pathogenesis of SSc and, therefore, may open the gate for extensive
future investigation to establish the role of these newly identified proteins in SSc development
and pathogenesis.
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